Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters
Abstract
:1. Introduction
2. Case Presentation
3. Discussion and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Correction Statement
References
- Lerkvaleekul, B.; Vilaiyuk, S. Macrophage activation syndrome: Early diagnosis is key. Open Access Rheumatol. Res. Rev. 2018, 10, 117–128. [Google Scholar] [CrossRef] [PubMed]
- Bode, S.F.N.; Ammann, S.; Al-Herz, W.; Bataneant, M.; Dvorak, C.C.; Gehring, S.; Gennery, A.; Gilmour, K.C.; Gonzalez-Granado, L.I.; Groß-Wieltsch, U.; et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: Implications for differential diagnosis and pathogenesis. Haematologica 2015, 100, 978–988. [Google Scholar] [CrossRef]
- Schmid, J.P.; Canioni, D.; Moshous, D.; Touzot, F.; Mahlaoui, N.; Hauck, F.; Kanegane, H.; Lopez-Granados, E.; Mejstrikova, E.; Pellier, I.; et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117, 1522–1529. [Google Scholar] [CrossRef]
- Bryceson, Y.T.; Pende, D.; Maul-Pavicic, A.; Gilmour, K.C.; Ufheil, H.; Vraetz, T.; Chiang, S.C.; Marcenaro, S.; Meazza, R.; Bondzio, I.; et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012, 119, 2754–2763. [Google Scholar] [CrossRef]
- Kogawa, K.; Lee, S.M.; Villanueva, J.; Marmer, D.; Sumegi, J.; Filipovich, A.H. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002, 99, 61–66. [Google Scholar] [CrossRef] [PubMed]
- Marsh, R.A.; Bleesing, J.J.; Filipovich, A.H. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J. Immunol. Methods 2010, 362, 1–9. [Google Scholar] [CrossRef]
- Sepulveda, F.E.; de Saint Basile, G. Hemophagocytic syndrome: Primary forms and predisposing conditions. Curr. Opin. Immunol. 2017, 49, 20–26. [Google Scholar] [CrossRef] [PubMed]
- Rouphael, N.G.; Talati, N.J.; Vaughan, C.; Cunningham, K.; Moreira, R.; Gould, C. Infections associated with haemophagocytic syndrome. Lancet Infect. Dis. 2007, 7, 814–822. [Google Scholar] [CrossRef]
- Wysocki, C.A. Comparing hemophagocytic lymphohistiocytosis in pediatric and adult patients. Curr. Opin. Allergy Clin. Immunol. 2017, 17, 405–413. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Xiong, L.; Tang, W.; Zhou, Y.; Li, F. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget 2017, 8, 59977–59985. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, T.; Matsuguma, M. Refractory hemophagocytic syndrome in a patient with acute myelocytic leukemia. Blood 2013, 121, 2820. [Google Scholar] [CrossRef]
- Daver, N.; McClain, K.; Allen, C.E.; Parikh, S.A.; Otrock, Z.; Rojas-Hernandez, C.; Blechacz, B.; Wang, S.; Minkov, M.; Jordan, M.B.; et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017, 123, 3229–3240. [Google Scholar] [CrossRef]
- Khadanga, S.; Solomon, B.; Dittus, K. Hemophagocytic lymphohistiocytosis (HLH) associated with T-cell lymphomas: Broadening our differential for fever of unknown origin. N. Am. J. Med. Sci. 2014, 6, 484–486. [Google Scholar] [CrossRef]
- Devitt, K.; Cerny, J.; Switzer, B.; Ramanathan, M.; Nath, R.; Yu, H.; Woda, B.A.; Chen, B.J. Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma. Leuk. Res. Rep. 2014, 3, 42–45. [Google Scholar] [CrossRef]
- Trebo, M.M.; Attarbaschi, A.; Mann, G.; Minkov, M.; Kornmüller, R.; Gadner, H. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study. Leuk. Lymphoma 2005, 46, 1735–1741. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, M.M.; Lee-Kim, Y.; George, T.I.; McClain, K.L.; Twist, C.J.; Jeng, M. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2008, 50, 381–383. [Google Scholar] [CrossRef] [PubMed]
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03367299 (accessed on 31 May 2021).
- Marks, D.I.; Kebriaei, P.; Stelljes, M.; Gökbuget, N.; Kantarjian, H.; Advani, A.S.; Merchant, A.; Stock, W.; Cassaday, R.D.; Wang, T.; et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol. Blood Marrow Transplant. 2019, 25, 1720–1729. [Google Scholar] [CrossRef] [PubMed]
- Kebriaei, P.; Cutler, C.; De Lima, M.; Giralt, S.; Lee, S.J.; Marks, D.; Merchant, A.; Stock, W.; Van Besien, K.; Stelljes, M. Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review. Bone Marrow Transplant. 2018, 53, 449–456. [Google Scholar] [CrossRef] [PubMed]
- Handous, I.; Achour, B.; Marzouk, M.; Rouis, S.; Hazgui, O.; Brini, I.; Khelif, A.; Hannachi, N.; Boukadida, J. Co-infections of human herpesviruses (CMV, HHV-6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy. Virol. J. 2020, 17, 1–15. [Google Scholar] [CrossRef]
- La Rosée, P.; Horne, A.C.; Hines, M.; Greenwood, T.V.B.; Machowicz, R.; Berliner, N.; Birndt, S.; Gil-Herrera, J.; Girschikofsky, M.; Jordan, M.B.; et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019, 133, 2465–2477. [Google Scholar] [CrossRef]
- Carter, S.J.; Tattersall, R.S.; Ramanan, A.V. Macrophage activation syndrome in adults: Recent advances in pathophysiology, diagnosis and treatment. Rheumatology 2019, 58, 5–17. [Google Scholar] [CrossRef] [PubMed]
- Gavand, P.E.; Serio, I.; Arnaud, L.; Costedoat-Chalumeau, N.; Carvelli, J.; Dossier, A.; Hinschberger, O.; Mouthon, L.; Le Guern, V.; Korganow, A.S.; et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun. Rev. 2017, 16, 743–749. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_it.pdf (accessed on 31 May 2021).
- Monteagudo, L.A.; Boothby, A.; Gertner, E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020, 2, 276–282. [Google Scholar] [CrossRef]
- CORIMUNO-ANA: Trial Evaluating Efficacy of Anakinra in Patients with Covid-19 Infection—Full Text View—ClinicalTrials.gov. Available online: https://www.clinicaltrials.gov/ct2/show/NCT04341584 (accessed on 31 May 2021).
- Shakoory, B.; Carcillo, J.A.; Chatham, W.W.; Amdur, R.L.; Zhao, H.; Dinarello, C.A.; Cron, R.Q.; Opal, S.M. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. Crit. Care Med. 2016, 44, 275–281. [Google Scholar] [CrossRef]
- Yang, B.B.; Baughman, S.; Sullivan, J.T. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther. 2003, 74, 85–94. [Google Scholar] [CrossRef]
- Clark, S.R.; McMahon, C.J.; Gueorguieva, I.; Rowland, M.; Scarth, S.; Georgiou, R.; Tyrrell, P.J.; Hopkins, S.J.; Rothwell, N.J. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cereb. Blood Flow Metab. 2008, 28, 387–394. [Google Scholar] [CrossRef] [PubMed]
- Mehta, P.; Cron, R.Q.; Hartwell, J.; Manson, J.J.; Tattersall, R.S. Silencing the cytokine storm: The use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020, 2, e358–e367. [Google Scholar] [CrossRef]
2004 Criteria of Histiocyte Society for HLH Diagnosis (At Least 5 of the Following 8 Criteria) |
---|
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Duminuco, A.; Palumbo, G.A.M.; Garibaldi, B.; Foti, R.; Di Raimondo, F.; Maugeri, C.; Mauro, E.; Fiumara, P.F.; Vetro, C. Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato 2021, 2, 347-352. https://doi.org/10.3390/hemato2020020
Duminuco A, Palumbo GAM, Garibaldi B, Foti R, Di Raimondo F, Maugeri C, Mauro E, Fiumara PF, Vetro C. Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato. 2021; 2(2):347-352. https://doi.org/10.3390/hemato2020020
Chicago/Turabian StyleDuminuco, Andrea, Giuseppe A. M. Palumbo, Bruno Garibaldi, Rosario Foti, Francesco Di Raimondo, Cinzia Maugeri, Elisa Mauro, Paolo F. Fiumara, and Calogero Vetro. 2021. "Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters" Hemato 2, no. 2: 347-352. https://doi.org/10.3390/hemato2020020
APA StyleDuminuco, A., Palumbo, G. A. M., Garibaldi, B., Foti, R., Di Raimondo, F., Maugeri, C., Mauro, E., Fiumara, P. F., & Vetro, C. (2021). Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato, 2(2), 347-352. https://doi.org/10.3390/hemato2020020